CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-19). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 697 · Search date 2026-07-19 · Methodology v0.6

AstraGin,
does it really help with Maximized muscle function and exercise effects through increased protein and creatine absorption?

30-Second Summary
C
Evidence Grade C · 42 · Safety unknown
Plasma amino-acid signals do not establish enhanced creatine uptake or long-term muscle and performance benefits
What the
research shows
AstraGin is rated C because a 30-person crossover pilot showed signals in amino-acid AUC after whey and selected four-week grip outcomes. The evidence is dominated by small pharmacokinetic surrogates, only ten participants per age stratum, coadministration with whey and resistance exercise, and study material supplied by the trademark owner NuLiv Science. Creatine absorption was not tested, and long-term hypertrophy or maximized exercise performance remains unconfirmed. The broad claim therefore receives C with 42 points.
What the
ads claim
Marketing expands small short-term differences in plasma amino-acid AUC into maximized absorption of protein and creatine, larger muscles, and superior performance. Human evidence centers on small pharmacokinetic studies of a particular branded ingredient coadministered with whey or arginine.
*

Useful facts when choosing a product

  • AstraGin is a branded combination of Astragalus membranaceus and Panax notoginseng saponin extracts and is not equivalent to generic astragalus or ginseng supplements.
  • Human pharmacokinetic trials mainly used 50 mg AstraGin with whey protein or arginine, which cannot substitute for a creatine-absorption trial.
  • Short trials reported no major liver or kidney signal, but sample size and duration are insufficient for long-term safety, pregnancy, lactation, or interaction conclusions.
  • Retail sports products may combine caffeine, creatine, amino acids, and other ingredients, preventing attribution of the finished-product effect to AstraGin alone.
Gap Measurement · Verdict 697 · C 42
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Lin et al. 2023 analyzed 24 participants given 5 g arginine with 50 mg APS and reported a 17.3% increase in arginine AUC, while Cmax and between-group urinary nitrate and cGMP differences were not significant. Zhuang et al. 2026 conducted a 30-person crossover pilot using whey protein plus 50 mg APS and reported immediate AUC differences of 6.67% for valine and 3.62% for leucine, with larger absorption and grip-change signals after four weeks. NuLiv Science supplied the study ingredient, and each age stratum contained only ten participants. The registry and published literature did not identify an isolated AstraGin comparison for creatine absorption, muscle creatine storage, long-term hypertrophy, or sport performance.

02

Why this is classified as C (42)

A 30-person pilot provides whey amino-acid AUC and selected four-week grip signals, supporting C only for the narrower protein and amino-acid absorption subclaim. Pharmacokinetic surrogates, tiny age strata, study material supplied by NuLiv Science, and coadministration with whey and resistance exercise limit attribution. Creatine absorption was not tested, and long-term hypertrophy or maximized exercise performance remains unconfirmed, so the broad claim receives C with 42 points.

Counterpoint. Muscle adaptation in people with adequate protein intake depends on total protein, resistance training, energy intake, and recovery. Established evidence for creatine itself must not be read as evidence that AstraGin enhances creatine.

Rejudgment record. New verdict — Accepted amino-acid pharmacokinetic signals from 24- and 30-person crossover trials but applied the rules ① and ②-b ceiling of C because creatine absorption, long-term hypertrophy, and performance were not directly tested and effects could not be isolated from whey, resistance training, or multi-ingredient products

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increased protein and amino-acid absorptionCA 30-person pilot showed selected amino-acid AUC signals after whey, but these were small pharmacokinetic surrogate outcomes.
Increased creatine absorption?No human efficacy literature directly tested creatine absorption or muscle creatine stores.
Maximized long-term hypertrophy and exercise performance?Only selected four-week grip signals exist, with no human trial confirming long-term hypertrophy or actual exercise performance.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Zhuang SR et al. 2026Randomized double-blind placebo-controlled crossover pilot trial10NuLiv Science supplied study capsules; academic studyAmino-acid AUC after whey, plus four-week grip strength, muscle mass, and gut-barrier measuresSelected BCAA AUC and four-week grip-change signals were reported, but this was a short pilot and did not test creatine.Key branded-ingredient surrogate trial
Lin CP et al. 2023Randomized double-blind placebo-controlled crossover pharmacokinetic trial24Funded by Chung Shan Medical University; NuLiv Science supplied capsulesArginine AUC and Cmax, ADMA, and urinary nitrate and cGMPArginine AUC increased by 17.3%, while Cmax and between-group urinary nitrate and cGMP differences were not significant.Additional absorption-surrogate signal
ClinicalTrials.gov NCT06110260Prospectively registered randomized double-blind crossover trial record30Chung Shan Medical University; AstraGin branded ingredient usedPrimary BCAA AUC; secondary grip strength and DXA muscle massRegistered outcomes centered on absorption pharmacokinetics rather than creatine uptake or sport performance.Scope and endpoint verification
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-19).

Zhuang SR, Yen CH, Lin KY, Shen YC. Effects of Astragalus membranaceus and Panax notoginseng Saponins Extract on the Pharmacokinetics of Whey Protein Absorption, Intestinal Permeability, and Muscle Function: A Pilot Study. Nutrients. 2026;18(3):504. PMID: 41683325. DOI: 10.3390/nu18030504.
checked
Lin CP, Lin CT, Wu IC, Pan TY, Shen YC. Pharmacokinetic effect of Astragalus membranaceus and Panax notoginseng saponins on arginine absorption and nitric oxide production in healthy subjects: a randomized, double-blind, cross-over trial. Funct Foods Health Dis. 2023;13(6):307-319. PMID: none. DOI: 10.31989/ffhd.v13i6.1104.
checked
ClinicalTrials.gov. Pharmacokinetic Effect of AstraGin on Whey Protein Absorption and Muscle Function in Healthy Subjects. NCT06110260. PMID: none. DOI: none.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none

Cite this verdict

AstraGin x maximized muscle function and exercise effects through increased protein and creatine absorption Evidence Grade C card
[Chamgap] AstraGin x maximized muscle function and exercise effects through increased protein and creatine absorption — Evidence Grade C·42. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/astragin-protein-creatine-absorption-muscle-performance/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.